OPTIMIZE

A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide as GvHD Prophylaxis in Adult Patients With Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

More Information

Trial Status
Accepting patients
Trial Phase
Phase 2
Enrollment
190 patients (estimated)
Sponsors
Center for International Blood and Marrow Transplant Research
Collaborators
National Marrow Donor Program (NMDP)
Tags
Allogeneic Stem Cell Transplant
Trial Type
Treatment
Last Update
1 month ago
SparkCures ID
1747
NCT Identifier
NCT06001385

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.